Skip to main content

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Contact information


amanda.adler@dtu.ox.ac.uk

Amanda Adler

Professor of Diabetic Medicine and Health Policy

  • Director of Diabetes Trials Unit
  • Chair NIHR Health Technology Assessment and Clinical Evaluation and Trial Committee
  • Commissioner, Commission on Human Medicines (CHM)
  • Chair, Cardiovascular, Diabetes, Renal, Respiratory and Allergy Expert Advisory Group, CHM
  • Honorary Consultant Physician

Amanda Adler trained in economics, medicine, pharmacovigilance, and pharmacoepidemiology.  She works closely with Health Economic Research Centre in Oxford and  research groups around the UK and internationally on clinical trials and health economic projects.  

She is a practicing clinician.

Within Oxford University, she teaches in the Management in Medicines Programme (Green Templeton College), the MSc in Clinical Trials, and the Economics of Health Care short course in addition to co-supervising DPhil and Masters students, NIHR academic clinical fellows, career development awardees, and lecturers. 

She is a Commissioner on the Commission on Human Medicines (CHM) which advises ministers on the safety, efficacy and quality of medicinal products, and chairs the CHM’s Expert Advisory Group Cardiovascular, Diabetes, Renal, Respiratory and Allergy.  She chairs the NIHR Clinical Evaluation and Trials Funding Committee.   She chairs the Pan American Health Organisation/WHO clinical guideline group on treating type 2 diabetes in the primary care setting. 

At the National Institute for Health and Care Excellence (NICE) she chaired a Technology Appraisal Committee for 12 years evaluating drugs and devices across disease areas.   She chaired the committee related to new models to evaluate and purchase antimicrobials, the In-Vitro Advisory Group during COVID, the Clinical Guidelines for Newer Agents for Type 2 Diabetes, and the Quality Standard for Diabetes. She supports NICE International and NICE Advice.  She received an award for Distinguished Contribution to NICE.